18 Jul Touchlight
Verna McErlane, Chief Commercial Officer
Oct. 6 | 9:15am | FLW Ballroom G
London, UK
(Private)
Touchlight is a leading, innovation-driven CDMO pioneering enzymatic GMP DNA production to enable the genetic medicine revolution. With an FDA Drug Master File accepted in 2022, followed in 2025 with the world’s first cell-free DNA GMP license, Touchlight’s enzymatic DNA technology is on the cutting edge of AAV, mRNA, DNA vaccine, and gene editing technology with its state-of-the-art facility recognised by ISPE’s Facility of the Year Awards (FOYA) for Innovation. With multiple client products already in the clinic, Touchlight’s evidence-based, synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development. The company and technology are built on the conviction that DNA is fundamental to the future of medicine. Founded in 2007, Touchlight’s team is inspired by breakthroughs in genetic medicine, recognising the urgent need for innovative DNA production techniques to support the future of genetic therapies.